DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2244198/biotech-stock-roundup-gern-crnx-gain-on-updates-bmy-s-car-t-cell-therapy-news-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2244198 Mar 21, 2024 - Geron Corporation (GERN) and Crinetics Pharmaceuticals (CRNX) gain on positive regulatory and study updates. 0

https://www.zacks.com/commentary/2246613/top-analyst-reports-for-meta-platforms-s-p-global-at-t?cid=CS-ZC-FT-research_daily-2246613 Mar 27, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), S&P Global Inc. (SPGI) and AT&T Inc. (T). 0

https://www.zacks.com/stock/news/2249211/comcast-s-cmcsa-xfinity-mobile-unveils-new-value-plans?cid=CS-ZC-FT-analyst_blog|company_news_-_corporate_actions-2249211 Apr 02, 2024 - Comcast's (CMCSA) Xfinity Mobile unveils new unlimited plans, offering more premium data and extra features compared with major telecom providers. 0

https://www.zacks.com/stock/news/2252143/will-t-rowe-trow-beat-estimates-again-in-its-next-earnings-report?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-2252143 Apr 08, 2024 - T. Rowe (TROW) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. 0

https://www.zacks.com/stock/news/2251984/analysts-estimate-m-t-bank-corporation-mtb-to-report-a-decline-in-earnings-what-to-look-out-for?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2251984 Apr 08, 2024 - M&T Bank (MTB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. 0

https://www.zacks.com/stock/news/2252179/bristol-myers-bmy-gets-fda-nod-for-label-expansion-of-abecma?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2252179 Apr 08, 2024 - Bristol Myers (BMY) wins FDA approval for CAR T cell immunotherapy, Abecma, in earlier lines of treatment for patients with relapsed or refractory multiple myeloma. 0

https://www.zacks.com/stock/news/2253218/unveiling-m-t-bank-mtb-q1-outlook-wall-street-estimates-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2253218 Apr 10, 2024 - Get a deeper insight into the potential performance of M&T Bank (MTB) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics. 0

https://www.zacks.com/stock/news/2254012/what-s-in-the-offing-for-m-t-bank-mtb-in-q1-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2254012 Apr 11, 2024 - Despite a rise in loans, increasing funding costs are likely to have hurt M&T Bank's (MTB) Q1 NII growth. Also, softer mortgage income is expected to have affected its non-interest income. 0

https://www.zacks.com/stock/news/2260553/t-rowe-price-trow-to-post-q1-earnings-what-to-expect?cid=CS-ZC-FT-analyst_blog|earnings_preview-2260553 Apr 23, 2024 - T. Rowe Price (TROW) is expected to have witnessed an improvement in AUM in the first quarter of 2024 due to a favorable equity market performance, partially offset by net outflows. 0

https://www.zacks.com/stock/news/2261409/at-t-t-q1-earnings-beat-estimates-revenues-remain-flat-y-y?cid=CS-ZC-FT-analyst_blog|earnings_article-2261409 Apr 24, 2024 - AT&T (T) surpasses first-quarter earnings estimates, backed by healthy 5G and fiber customer additions and strong cash flow. 0